➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Mallinckrodt
McKesson
Boehringer Ingelheim
Moodys

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

TRUSOPT Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Trusopt patents expire, and what generic alternatives are available?

Trusopt is a drug marketed by Merck and is included in one NDA.

The generic ingredient in TRUSOPT is dorzolamide hydrochloride. There are fifteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dorzolamide hydrochloride profile page.

Drug patent expirations by year for TRUSOPT
Drug Prices for TRUSOPT

See drug prices for TRUSOPT

Drug Sales Revenue Trends for TRUSOPT

See drug sales revenues for TRUSOPT

Recent Clinical Trials for TRUSOPT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Eye Institute (NEI)Phase 1/Phase 2
National Eye Institute (NEI)Phase 3
University of MiamiPhase 3

See all TRUSOPT clinical trials

Pharmacology for TRUSOPT
Paragraph IV (Patent) Challenges for TRUSOPT
Tradename Dosage Ingredient NDA Submissiondate
TRUSOPT SOLUTION/DROPS;OPHTHALMIC dorzolamide hydrochloride 020408 2005-10-11

US Patents and Regulatory Information for TRUSOPT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck TRUSOPT dorzolamide hydrochloride SOLUTION/DROPS;OPHTHALMIC 020408-001 Dec 9, 1994 AT RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRUSOPT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck TRUSOPT dorzolamide hydrochloride SOLUTION/DROPS;OPHTHALMIC 020408-001 Dec 9, 1994 ⤷  Try it Free ⤷  Try it Free
Merck TRUSOPT dorzolamide hydrochloride SOLUTION/DROPS;OPHTHALMIC 020408-001 Dec 9, 1994 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for TRUSOPT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0509752 C990041 Netherlands ⤷  Try it Free PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0509752 SPC/GB99/043 United Kingdom ⤷  Try it Free PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
0296879 96C0003 Belgium ⤷  Try it Free PRODUCT NAME: HYDROCHLORIDUM, EQ. DORZOLAMIDUM; NAT. REGISTRATION NO/DATE: 922 IS 168 F13 19951019; FIRST REGISTRATION: SE 12208 19941219
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Mallinckrodt
McKesson
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.